Literature DB >> 30734894

Overlap Between GERD and Functional Esophageal Disorders-a Pivotal Mechanism for Treatment Failure.

Ofer Z Fass1, Ronnie Fass2.   

Abstract

ᅟRefractory GERD is very common, and while many different underlying mechanisms have been identified, the main focus has remained on residual reflux (acidic or non-acidic). Recently, Rome IV introduced two new concepts with important impact on patients with refractory GERD. They include the introduction of the reflux hypersensitivity group and the proposal that GERD can overlap with a functional esophageal disorder. Recent studies have demonstrated that the latter affects approximately three quarters of the GERD patients who failed PPI once daily.

Entities:  

Keywords:  Esophagus; Functional heartburn; GERD; Heartburn; PPI; Reflux hypersensitivity

Year:  2019        PMID: 30734894     DOI: 10.1007/s11938-019-00224-7

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  22 in total

Review 1.  Epidemiology of gastro-oesophageal reflux disease: a systematic review.

Authors:  J Dent; H B El-Serag; M-A Wallander; S Johansson
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 2.  Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?

Authors:  R Fass; M Shapiro; R Dekel; J Sewell
Journal:  Aliment Pharmacol Ther       Date:  2005-07-15       Impact factor: 8.171

3.  Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication.

Authors:  I Mainie; R Tutuian; A Agrawal; D Adams; D O Castell
Journal:  Br J Surg       Date:  2006-12       Impact factor: 6.939

4.  The role of esophageal pH monitoring in symptomatic patients on PPI therapy.

Authors:  Samer Charbel; Farah Khandwala; Michael F Vaezi
Journal:  Am J Gastroenterol       Date:  2005-02       Impact factor: 10.864

5.  The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.

Authors:  Nimish Vakil; Sander V van Zanten; Peter Kahrilas; John Dent; Roger Jones
Journal:  Am J Gastroenterol       Date:  2006-08       Impact factor: 10.864

6.  Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH.

Authors:  M F Vela; R Tutuian; P O Katz; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  2003-01       Impact factor: 8.171

7.  Relationship between symptom response and oesophageal acid exposure after medical and surgical treatment for gastro-oesophageal reflux disease.

Authors:  A D Jenkinson; S S Kadirkamanathan; S M Scott; E Yazaki; D F Evans
Journal:  Br J Surg       Date:  2004-11       Impact factor: 6.939

8.  Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily.

Authors:  Anita Gasiorowska; Tomas Navarro-Rodriguez; Christopher Wendel; Elizabeth Krupinski; Zvi H Perry; Kristina Koenig; Bridget Moty; Jeannette Powers; Ronnie Fass
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

9.  Characteristics of symptomatic reflux episodes on Acid suppressive therapy.

Authors:  Radu Tutuian; Marcelo F Vela; Elizabeth G Hill; Inder Mainie; Amit Agrawal; Donald O Castell
Journal:  Am J Gastroenterol       Date:  2008-04-28       Impact factor: 10.864

10.  Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring.

Authors:  I Mainie; R Tutuian; S Shay; M Vela; X Zhang; D Sifrim; D O Castell
Journal:  Gut       Date:  2006-03-23       Impact factor: 23.059

View more
  3 in total

1.  Treatment of Refractory Gastroesophageal Reflux Disease.

Authors:  Rishi D Naik; Matthew H Meyers; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

Review 2.  Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.

Authors:  Fahmi Shibli; Yoshitaka Kitayama; Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2020-03-17

3.  Prevalence of CYP2C19 polymorphism in Bogotá, Colombia: The first report of allele *17.

Authors:  Azucena Arévalo-Galvis; William A Otero-Regino; Gloria N Ovalle-Celis; Eliana R Rodríguez-Gómez; Alba A Trespalacios-Rangel
Journal:  PLoS One       Date:  2021-01-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.